Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.41 |
| ▸ | IL1B | P01584 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27182186 | 0.90 | NLRP3 (0.43) | NLRP3IL1BSCN9AKCNH2TNF | |
| SCHEMBL29326142 | 0.85 | IL1B (0.44) | NLRP3IL1BHDAC4HDAC6SCN9A | |
| SCHEMBL29326121 | 0.82 | IL1B (0.47) | NLRP3IL1BHDAC4HDAC6JAK2 | |
| SCHEMBL29326158 | 0.81 | IL1B (0.41) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL29326138 | 0.80 | TRPV1 (0.44) | NLRP3IL1BKCNH2 | |
| SCHEMBL29326150 | 0.79 | IL1B (0.52) | NLRP3IL1BHDAC4HDAC6KCNH2 | |
| SCHEMBL29974698 | 0.79 | IL1B (0.52) | NLRP3IL1BHDAC4HDAC6KCNH2 | |
| SCHEMBL29326412 | 0.79 | NLRP3 (0.48) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL29326688 | 0.78 | NLRP3 (0.48) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL30685036 | 0.78 | EPHA2 (0.39) | HDAC4HDAC6P2RX3P2RX2EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4345097-A1 | SUBSTITUTED TRIAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2024-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885IL1B 11/4885HDAC4 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.